TissueGen CSO to Deliver Keynote Session at Purdue University’s Biomedical Engineering Graduate Student Association Research Symposium

03 Feb TissueGen CSO to Deliver Keynote Session at Purdue University’s Biomedical Engineering Graduate Student Association Research Symposium

Dr. Kevin Nelson to Speak on “Falling up: Life Lessons Learned Moving from the Black Board to the Board Room” on February 5th

Dallas, TX, February 3, 2015 – Dr. Kevin Nelson, founder and CSO of TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, will be the keynote speaker at Purdue University’s Biomedical Engineering Graduate Student Association (BMEGSA) Research Symposium on Thursday, February 5th from 3:30 to 4:40pm.

Dr. Nelson’s session, titled Falling up: Life Lessons Learned Moving from the Black Board to the Board Room,” will detail his professional experiences. In 1996, Dr. Nelson – then a faculty member in Biomedical Engineering at the University of Texas at Arlington (UTA) – joined a team working on an NIH grant to develop a fiber-based, biodegradable vascular stent with the goal of delivering gene therapy to the vessel wall. Simultaneously working with Dr. Nathan Schwade to develop drug-loaded microspheres for improved wound healing, he eventually combined the drug-loading techniques of microspheres with the fiber for the biodegradable stent, and fiber-based drug delivery was born. Eventually patented, this technology has been the focus of Dr. Nelson’s professional life and the driver behind TissueGen, Inc.

“Transitioning from UTA to founder and CSO of TissueGen has been an exciting – and sometimes challenging – path that has enabled me to drive new breakthroughs in the way drug delivery, nerve regeneration and tissue engineering can be approached,” said Dr. Nelson. “I am delighted to share my experiences with the attendees at this year’s BMEGSA Research Symposium and it’s an honor to be invited as the keynote speaker.”

About TissueGen

TissueGen® Inc. has more than four decades of cumulative experience in extruding biodegradable polymer fibers with broad drug delivery capabilities well-suited for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen offers the medical market a portfolio of issued patents on unique drug delivery technology with the capability to incorporate and elute a broad range of biologically derived therapeutics and standard pharmaceuticals in hydrophobic, biodegradable polymeric fibers or tubes for sustained therapeutic release. For more information, please visit www.tissuegen.com.

# # #

 

For more information contact:

Jordan Bouclin

SVM Public Relations

401-490-9700

jordan.bouclin@svmpr.com

 

 

 

No Comments

Sorry, the comment form is closed at this time.